Amicogen Inc (092040) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Amicogen Inc (092040) has a cash flow conversion efficiency ratio of -0.027x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-3.58 Billion ≈ $-2.43 Million USD) by net assets (₩133.35 Billion ≈ $90.37 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Amicogen Inc (092040) net asset quality to measure how much of total assets are equity-financed.
Amicogen Inc - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Amicogen Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how high is Amicogen Inc's earnings quality to evaluate the quality of earnings relative to operating cash generation.
Amicogen Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Amicogen Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Madusari Murni Indah Tbk PT
JK:MOLI
|
0.092x |
|
TechPrecision Corporation Common stock
NASDAQ:TPCS
|
0.023x |
|
Entain PLC
LSE:ENT
|
0.282x |
|
Orient Paper & Industries Limited
NSE:ORIENTPPR
|
-0.008x |
|
Defiance Silver Corp
V:DEF
|
-0.010x |
|
SMS Lifesciences India Limited
NSE:SMSLIFE
|
0.153x |
|
DKLS Industries Bhd
KLSE:7528
|
0.017x |
|
Exel Composites Oyj
HE:EXL1V
|
0.102x |
Annual Cash Flow Conversion Efficiency for Amicogen Inc (2014–2025)
The table below shows the annual cash flow conversion efficiency of Amicogen Inc from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see 092040 market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩95.86 Billion ≈ $64.96 Million |
₩-24.42 Billion ≈ $-16.55 Million |
-0.255x | -134.05% |
| 2024-12-31 | ₩122.50 Billion ≈ $83.01 Million |
₩-13.34 Billion ≈ $-9.04 Million |
-0.109x | -375.82% |
| 2023-12-31 | ₩218.97 Billion ≈ $148.40 Million |
₩8.64 Billion ≈ $5.86 Million |
0.039x | +123.21% |
| 2022-12-31 | ₩131.80 Billion ≈ $89.32 Million |
₩-22.41 Billion ≈ $-15.19 Million |
-0.170x | -492.13% |
| 2021-12-31 | ₩186.16 Billion ≈ $126.16 Million |
₩8.07 Billion ≈ $5.47 Million |
0.043x | -25.19% |
| 2020-12-31 | ₩152.94 Billion ≈ $103.65 Million |
₩8.87 Billion ≈ $6.01 Million |
0.058x | -19.24% |
| 2019-12-31 | ₩122.05 Billion ≈ $82.71 Million |
₩8.76 Billion ≈ $5.94 Million |
0.072x | +221.69% |
| 2018-12-31 | ₩127.28 Billion ≈ $86.26 Million |
₩2.84 Billion ≈ $1.92 Million |
0.022x | -83.25% |
| 2017-12-31 | ₩89.19 Billion ≈ $60.44 Million |
₩11.88 Billion ≈ $8.05 Million |
0.133x | -3.68% |
| 2016-12-31 | ₩81.54 Billion ≈ $55.26 Million |
₩11.28 Billion ≈ $7.64 Million |
0.138x | -8.00% |
| 2015-12-31 | ₩82.10 Billion ≈ $55.64 Million |
₩12.34 Billion ≈ $8.36 Million |
0.150x | +69.90% |
| 2014-12-31 | ₩50.02 Billion ≈ $33.90 Million |
₩4.43 Billion ≈ $3.00 Million |
0.088x | -- |
About Amicogen Inc
Amicogen, Inc. operates as an industrial biotechnology company in South Korea and internationally. The company develops, produces, and sells of enzymes and new materials; and produces food-related additives and health functional food. It manufactures and sells of biopharmaceutical materials and resins for purifying pharmaceutical proteins and health and beauty products. In addition, the company o… Read more